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Background: Neuropathic pain (NP) is an incurable disease caused by a primary lesion in
the nervous system. NP is a progressive nervous system disease that results from poorly
deﬁned neurophysiological and neurochemical changes. Its treatment is very difﬁcult. Cur-
rent available therapeutic drugs have a generalized nature, sometime acting only on the
temporal pain properties rather than targeting the several mechanisms underlying the gen-
eration and propagation of pain. Methods: Using biomolecular and immunohistochemical
methods,we investigated the effect of the systemic injection of humanmesenchymal stem
cells (hMSCs) onNP relief.We used the spared nerve injury (SNI)model of NP in themouse.
hMSCs were injected into the tail vein of the mouse. Stem cell injection was performed
4days after sciatic nerve surgery. Neuropathic mice were monitored every 10 days start-
ing from day 11 until 90 days after surgery. Results: hMSCs were able to reduce pain-like
behaviors, such asmechanical allodynia and thermal hyperalgesia, once injected into the tail
vein. An anti-nociceptive effect was detectable from day 11 post surgery (7 days post cell
injection). hMSCsweremainly able to home in the spinal cord and pre-frontal cortex of neu-
ropathic mice. Injected hMSCs reduced the protein levels of the mouse pro-inﬂammatory
interleukin IL-1β and IL-17 and increased protein levels of themouse anti-inﬂammatory inter-
leukin IL-10, and themarker of alternatively activatedmacrophages CD106 in the spinal cord
of SNI mice. Conclusion: As a potential mechanism of action of hMSCs in reducing pain,
we suggest that they could exert their beneﬁcial action through a restorative mechanism
involving: (i) a cell-to-cell contact activation mechanism, through which spinal cord homed
hMSCs are responsible for switching pro-inﬂammatory macrophages to anti-inﬂammatory
macrophages; (ii) secretion of a broad spectrum of molecules to communicate with other
cell types. This study could provide novel ﬁndings in MSC pre-clinical biology and their
therapeutic potential in regenerative medicine.
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INTRODUCTION
Chronic pain, deﬁned as pain that extends beyond the expected
period of healing (Merskey and Bogduk, 1994), can be classi-
ﬁed as nociceptive pain and neuropathic pain (NP): the ﬁrst one
derives from direct activation of peripheral nociceptors following
a tissue damage and it is associated with inﬂammation. NP is a
progressive nervous system disease, occurring in association with
a primary lesion or dysfunction in the nervous system. It could
be often associated with a continuous burning character together
with the presence of abnormal sensory symptoms, such as hyper-
algesia (an increased response to a stimulus which is normally
painful; patients with hyperalgesia perceive pain spontaneously)
and allodynia (pain as a result of a stimulus which does not pro-
voke pain; patients with allodynia do not feel constant pain; indeed
in the absence of a stimulus there is no pain; Merskey and Bog-
duk, 1994; Siniscalco et al., 2005a). NP is difﬁcult to treat and
often unresponsive to all available therapies. The array of drugs
available today in the treatment of NP indicates a heavy reliance on
“second-indication” drugs, which were initially developed to treat
other primary indications (e.g., anticonvulsants, antidepressants;
Galluzi, 2005; Siniscalco et al., 2005b).
Nowadays, stem cell therapy represents the greatest promise
for the future of molecular medicine (Siniscalco et al., 2007). Stem
cells could be neuroprotective in a variety of nervous system injury
models (Cao et al., 2002; Lindvall and Kokaia, 2005, 2006). Similar
to neurodegenerative diseases, NP appears to be amenable to stem
cell therapy (Klass et al., 2007; Siniscalco, 2010).
Stem cell populations comprise several kinds of undifferen-
tiated cells; among these, mesenchymal stem cells (MSCs) are
believed to have the best potential results in pain–care research
(Klass et al., 2007). Indeed, the ease of human mesenchymal stem
cell (hMSC) isolation from adult tissues and the fact they are not
ethically restricted make them attractive potential candidates for
use in cell therapy. In addition, their strong immunosuppressive
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properties render themuseful for transplantations,without requir-
ing a pharmacological immunosuppression (Le Blanc and Pit-
tenger, 2005; Beggs et al., 2006; Petrie Aronin and Tuan, 2010).
Their unique anti-inﬂammatory immunomodulatory phenotype
is another valuable property that can be used in diseases such as
NP, where a controlled inﬂammatory response is required. These
cells are a select population of progenitor cells of mesodermal ori-
gin found in the adult bone marrow, but can also be found in
the perivascular regions of most tissues, such as adipose, skeletal
muscle, and the umbilical cord (Zuk et al., 2002; Sarugaser et al.,
2005). MSCs demonstrate an ability to differentiate along several
tissue-speciﬁc lineages, a high expansion potential, genetic stabil-
ity, stable phenotype, and a self-renewing capacity (Giordano et al.,
2007; Pricola et al., 2009).
In NP models, MSCs have been observed to modulate pain
behavior after sciatic nerve injury (Musolino et al., 2007), although
their exact mechanism of action on pain behavior requires further
clariﬁcation.Moreover,we already demonstrated that hMSCswere
able to reduce short-term pain-like behaviors and modify pain-
related molecular mechanisms once transplanted into the cerebral
ventricle of neuropathic mice (Siniscalco et al., 2010).
However in the present study, we have used the spared nerve
injury (SNI) mouse model of NP to investigate the effects of sys-
temic intravenous administration of hMSCs on long-term pain-
associated behavior and on cellular and molecular mechanisms
underlying the development and maintenance of NP.
MATERIALS AND METHODS
ANIMALS
Male CD-1 mice (35–40 g) were housed three per cage under con-
trolled illumination (12:12 h light:dark cycle; light on 06.00 h) and
environmental conditions (room temperature 20–22˚C, humidity
55–60%) for at least 1 week before the commencement of experi-
ments. Mouse chow and tap water were available ad libitum. The
experimental procedures were approved by the Ethic Committee
of the Second University of Naples. Animal care was in compliance
with the IASP and European Community (E.C. L358/1 18/12/86)
guidelines on the use and protection of animals in experimen-
tal research. All efforts were made to minimize animal suffering
and to reduce the number of animals used. Behavioral testing
was performed before surgery to establish a baseline for com-
parison with post-surgical values. Mononeuropathy was induced
according to the method of Bourquin and Decosterd (Bourquin
et al., 2006). Mice were anesthetized with sodium pentobarbital
(60 mg/kg i.p.). The right hindlimb was immobilized in a lateral
position and slightly elevated. Incision was made at mid-thigh
level using the femur as a landmark. The sciatic nerve was exposed
at mid-thigh level distal to the trifurcation and freed of connective
tissue; the three peripheral branches (sural, commonperoneal, and
tibial nerves) of the sciatic nerve were exposed without stretching
nerve structures. Both tibial and common peroneal nerves were
ligated and transacted together. A micro-surgical forceps with
curved tips was delicately placed below the tibial and common
peroneal nerves to slide the thread (5.0 silk, Ethicon, Johnson, and
Johnson Intl,Brussels,Belgium) around the nerves.A tight ligation
of both nerves was performed. The sural nerve was carefully pre-
served by avoiding any nerve stretch or nerve contact with surgical
tools. Muscle and skin were closed in two distinct layers with silk
5.0 suture. Intense, reproducible and long-lasting thermal hyper-
algesia and mechanical allodynia-like behaviors are measurable in
the non-injured sural nerve skin territory (Bourquin et al., 2006).
The SNI model offers the advantage of a distinct anatomical distri-
bution with an absence of co-mingling of injured and non-injured
nerve ﬁbers distal to the lesion such as the injured and non-injured
nerves and territories can be readily identiﬁed and manipulated
for further analysis (i.e., behavioral assessment).
The sham procedure consisted of the same surgery without
ligation and transection of the nerves.
Groups of mice were divided as follows:
(i) Naïve (n = 9);
(ii) Sham-operated mice (n = 9);
(iii) SNI mice treated with vehicle (SNI/vehicle; n = 18);
(iv) SNI mice treated with hMSCs (2× 106 cells/100 μl;
SNI/hMSCs; n = 18).
On day 30 after surgery, mice were divided into further groups:
(a) groups for RT-PCR examination (three naive mice, three sham
mice, six SNI/vehicle mice, and six SNI/hMSCs mice), (b) groups
for western blot examination (three naive mice, three sham mice,
six SNI/vehicle mice, and six SNI/hMSCs mice), (c) groups for
histological examination (three naive mice, three sham mice, six
SNI/vehicle mice, and six SNI/hMSCs mice).
NOCICEPTIVE BEHAVIOR
Thermal hyperalgesia was evaluated by using a Plantar Test Appa-
ratus (Ugo Basile, Varese, Italy). On the day of the experiment
each animal was placed in a plastic cage (22 cm× 17 cm× 14 cm;
length×width× height) with a glass ﬂoor. After a 60-min habit-
uation period, the plantar surface of the hind paw was exposed to
a beam of radiant heat through the glass ﬂoor. The radiant heat
source consisted of an infrared bulb (Osram halogen-bellaphot
bulb; 8V, 50W). A photoelectric cell detected light reﬂected from
the paw and turned off the lamp when paw movement interrupted
the reﬂected light. The paw withdrawal latency (PWL) was auto-
matically displayed to the nearest 0.1 s; the cut-off time was 20 s in
order to prevent tissue damage.
Mechanical allodynia was measured by using Dynamic Plan-
tar Anesthesiometer (Ugo Basile, Varese, Italy). Mice were allowed
to move freely in one of the two compartments of the enclosure
positioned on the metal mesh surface. Mice were adapted to the
testing environment before any measurements were taken. After
that, the mechanical stimulus was delivered to the plantar surface
of the hindpaw of the mouse from below the ﬂoor of the test
chamber by an automated testing device. A steel rod (2 mm) was
pushed with electronical ascending force (0–30 g in 10 s). When
the animal withdrawn its hindpaw, the mechanical stimulus was
automatically withdrawn and the force recorded to the nearest
0.1 g. Nociceptive responses for thermal and mechanical sensitiv-
ity were expressed as thermal PWL in seconds and mechanical paw
withdrawal threshold (PWT) in grams.
Each mouse served as its own control, the responses being mea-
sured both before and after surgical procedures. PWL and PWT
were quantiﬁed by an observer blinded to the treatment.
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MOTOR COORDINATION BEHAVIOR
Neurological functions and motor coordination were evaluated by
Rotarod motor test (Ugo Basile, Varese, Italy). This test consists of
putting the mouse on a rotary cylinder in order to then measure
the time (in seconds) of its equilibrium before falling. The cylinder
is subdivided in ﬁve sections, allowing the screening of ﬁve ani-
mals per test (one for section), simultaneously. Below the cylinder
there is a platform in its turn subdivided in ﬁve plates (in corre-
spondence of the ﬁve sections) everyone of which it is connected
to a magnet that, activated from the fall of the mouse on the plate,
records the time of permanence on the cylinder. After a period of
adaptation of 30 s, the spin speed gradually increased from 5 to
40 g for the maximum time of 5 min. On the same day, the ani-
mals were analyzed by two separate tests with a time interval of
1 h. The experiment was performed for every group of animals:
the day before the surgical procedure, the day before the behav-
ioral tests in order to avoid useless stress and the day before the
stem cell administration. The time of permanence of the mouse
on the cylinder was expressed as latency(s).
HUMAN MESENCHYMAL STEM CELL CULTURES
Human bone marrow derived MSCs were isolated from a small
aspirate of bone marrow and in vitro expanded in basic-ﬁbroblast
growth factor (FGF)-containing medium as already described
(Siniscalco, 2010; Siniscalco et al., 2010). Shortly, bone marrows
were obtained from healthy donors after informed consent. Bone
marrow aspirates were collected from iliac crests, separated on
Ficoll density gradient (GE Healthcare, Italy), and the mononu-
clear cell fraction was harvested and washed in phosphate buffer
saline (PBS; Sigma, St. Louis, MO, USA). 1–2.5∗105 cells/cm2
were seeded in 100 mm dishes with α-modiﬁed Eagle’s medium
(α-MEM; Lonza, Verviers, Belgium) containing 10% fetal bovine
serum (FBS; EuroClone, Celbio, Milan, Italy), 2 ng/ml basic FGF
(PeproTech, Rocky Hill, NJ, USA), 2 mM l-glutamine (Lonza,
Verviers, Belgium), 100 U/ml penicillin (Lonza, Verviers, Bel-
gium), and 100 mg/ml streptomycin (Lonza, Verviers, Belgium;
proliferating medium). After 24–48 h, non-adherent cells were
discarded, and adherent cells representing MSCs along with com-
mitted progenitors were washed twice with PBS. Cells were then
incubated for 7–10 days in proliferating medium to reach conﬂu-
ence and extensively propagated for further experiments. We used
cells till the sixth passage, each time we plated 2 × 103 cells/cm2.
We routinely characterized hMSCs by staining for the mes-
enchymal stem cell cyto-speciﬁc markers CD73, CD90, and
CD105, as already described (Siniscalco, 2010; Siniscalco et al.,
2010).
HUMAN MESENCHYMAL STEM CELL TRANSPLANTATION PROCEDURE
On the day of the administration, hMSCs were microinjected into
the tail vein by using an 1-ml syringe. A volume of 100 μl solution
(stem cells + vehicle) or vehicle were injected. hMSCs were sus-
pended in PBS with 10% heparin and transplanted to neuropathic
mice, while control mice were administered with 100 μl PBS with
10% heparin (vehicle solution). Immediately prior to administra-
tion, hMSCs were maintained at room temperature, and they were
gently re-suspended with a pipette to ensure they were not aggre-
gated before infusion. We used heparin in the injection solution
in order to avoid cell cluster formation (Siniscalco et al., 2010).
Each neuropathic mice received 2× 106 cells/100 μl. The amount
of cells to be injected was chosen on the basis of a previous
study (Lee et al., 2009). In addiction, it has been observed that
a higher number of cells may cause cell cluster formation within
the microinjection cannula which, in turn, may be responsible of
cell damaging and decreased viability. After the administration,
antibiotic was applied to the injection area to prevent infection.
Immunosuppressants were not used in any animal.
Stem cells injection was performed 4 days after sciatic nerve
surgery. Neuropathic mice were monitored every 10 days starting
from day 11 until 90 days after surgery.
RNA EXTRACTION AND RT-PCR
Total RNA was extracted from homogenized mouse sciatic nerve,
lung, lumbar L4–L5 spinal cord (from ventral and dorsal areas,
respectively), and pre-frontal cortex using an RNA Tri-Reagent
(Molecular Research Center Inc., Cincinnati, OH, USA) accord-
ing to the manufacturer’s protocol. The total RNA concentration
was determined by UV spectrophotometer. The mRNA levels
of the glyceraldehyde phosphate dehydrogenase (GAPDH ) gene
under analysis were measured by RT-PCR ampliﬁcation, as pre-
viously reported (Siniscalco et al., 2010). Reverse transcriptase
from avian myeloblastosis virus (AMV-RT; Promega, Madison,
WI,USA) was used. Brieﬂy, for ﬁrst-strand cDNA synthesis 100 ng
total RNA, random examers, dNTPs (Promega, Madison, WI,
USA), AMV buffer, AMV-RT, and recombinant RNasin ribonu-
clease inhibitor (Promega, Madison, WI, USA) were assembled
in diethyl-pyrocarbonate-treated water to a 20-μl ﬁnal volume
and incubated 10 min at 65˚C and 1 h at 42˚C. Aliquots of 3μl
cDNA were transferred into a 25-μl PCR reaction mixture con-
taining dNTPs, MgCl2 buffer, speciﬁc primers, and GoTaq Flexi
DNA polymerase (Promega, Madison, WI, USA) and ampliﬁca-
tion reactions using speciﬁc primers and conditions for human
GAPDH cDNA were carried out. RT minus controls were carried
out to check potential genomic DNA contamination. These RT
minus controls were performed without using the reverse tran-
scriptase enzyme in the reaction mix. Sequence for the human
mRNA from GenBank (DNASTAR Inc., Madison, WI, USA) was
used to design speciﬁc primer pairs for RT-PCRs (OLIGO 4.05
software, National Biosciences Inc., Plymouth, MN, USA; primers
available on request). Each RT-PCR was repeated at least three
times to achieve best reproducibility data. The mean of the inter-
assay variability of each RT-PCR assays was 0.07. PCR products
were resolved into 2.0% agarose gel.
PROTEIN EXTRACTION AND WESTERN BLOT ANALYSIS
For the protein extraction, the lumbar L4–L5 segment of spinal
cord was minced into small pieces with a blender on ice,
then was suspended in lysis buffer (Tris/HCl 50 mM, pH 7.4;
NaCl 250 mM; 0.1% Triton X-100; Protease Inhibitor Cocktail
(Roche, Mannheim, Germany); NaF 0.05 M; Na3VO4 0.1 mM;
PMSF 100 μg/ml) containing 6 M urea. The protein concen-
tration was determined by the method described by Bradford
(1976). Each sample was loaded, electrophoresed in a 15% SDS-
polyacrylamide gel (8% for CD206 detection) and electroblotted
onto a nitrocellulose membrane. The membrane was blocked in
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5% milk, 1× Tris-buffered saline, 0.05% Tween-20. Primary anti-
bodies (Santa Cruz Biotechnology, Santa Cruz,CA,USA) to detect
IL-1β, IL-17, IL-10, and CD106 were used according to the manu-
facturer at 1:500 dilutions. Immunoreactive signals were detected
with a horseradish peroxidase-conjugated secondary antibody and
reacted with an ECL system (Amersham Pharmacia,Uppsala, Swe-
den). Protein levels were normalized with respect to the signal
obtained with anti-β-tubulin monoclonal antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA, USA; 1:1000 dilution). The semi-
quantitative analysis of protein levels was carried out by the “Gel
Doc 2000 UV System” (Bio-Rad, Hercules, CA, USA).
FLUORESCENCE IMMUNOHISTOCHEMISTRY
Animals were perfused transcardially with 150 ml of saline solu-
tion (0.9% NaCl), and 250 ml of 4% paraformaldehyde ﬁxative.
The L4–L5 spinal cord was taken out and kept in the ﬁxative for
24 h at 4˚C. The tissue was kept in 30% sucrose in PBS and frozen
in cryostat embedding medium (Bio-Optica, Milan, Italy). Serial
15 μm sections of the L4–L5 spinal cord were cut using a cryo-
stat and thaw-mounted onto glass slides. After washing in PBS,
non-speciﬁc antibody binding was inhibited by incubation for
30 min in blocking solution (1% BSA, 0.2% powdered skim milk,
0.3% Triton X-100 in PBS). Primary antibodies were diluted in
PBS blocking buffer and slides were incubated overnight at 4˚C
in primary antibodies to mouse monoclonal anti-CD73 (1:200;
Abcam, Cambridge, UK), to goat monoclonal anti-interleukin
1β (IL-1β, 1:200; Santa Cruz Biotech, CA, USA), to rat poly-
clonal anti-interleukin 17 (IL-17, 1:200; Santa Cruz Biotech, CA,
USA), to mouse monoclonal anti-CD4 (1:250; Santa Cruz Biotech,
CA, USA), to rabbit poly-clonal anti-Glial Fibrillary Acid Pro-
tein (GFAP, 1:1000; Dako Cytomation, Denmark), and to rabbit
poly-clonal anti-ionized calcium binding adapter molecule1 (Iba-
1, 1:500; Wako Chemicals, Japan). Fluorescent-labeled secondary
antibodies (1:500; Alexa Fluor 488, 568, Molecular Probe, Invit-
rogen, Carlsbad, CA, USA) speciﬁc to the IgG species used as
a primary antibody were used to locate the speciﬁc antigens in
each section. Sections were mounted with Vectashield containing
DAPI mounting medium (Vector Laboratories, Burlingame, CA,
USA). Fluorescently labeled sections were viewed with a ﬂuores-
cence microscope (Leica,Wetzlar, Germany) to locate the cells and
identify the spinal cord area. Immunoﬂuorescence images of four
stained sections were taken for each animal.
STATISTICAL ANALYSIS
Behavioral and molecular data are shown as mean ± SEM.
ANOVA, followed by Student–Neuman–Keuls post hoc test, was
used to determine the statistical signiﬁcance among groups.
p< 0.05 was considered statistically signiﬁcant.
RESULTS
HUMAN MESENCHYMAL STEM CELL ADMINISTRATION IN
NEUROPATHIC MICE REDUCES MECHANICAL ALLODYNIA, THERMAL
HYPERALGESIA, AND DOES NOT AFFECT MOTOR FUNCTION
Neuropathic mice were subjected to intravenous stem cell admin-
istration 4 days after sciatic nerve injury and were monitored every
10 days starting from day 11 until 90 days post surgery.We injected
hMSCswhenNPwas already established (4 days after SNI surgery)
in order to assess their potential role as a therapeutic tool in
long-term pain care. hMSCs were able to reduce pain-like behav-
iors such as mechanical allodynia and thermal hyperalgesia once
intravenously injected (Figures 1A,B).
Nociceptive responses to thermal andmechanical stimuli (PWL
and PWT, respectively) were measured every 30 min for 3 h before
surgery or every 10 days starting fromday 11 until 90 days after sci-
atic nerve surgery. The mean PWL and PWT was calculated from
six consecutive trials (each performed every 30 min) and averaged
for each group of mice.
Sham mice treated with vehicle did not show any change in
PWL or PWT compared to the naïve mice (data not shown).
SNI mice treated with vehicle developed mechanical allodynia
and thermal hyperalgesia on the ipsilateral side at all time points
that we analyzed, compared to sham mice treated with vehicle
(Figures 1A,B), although not on the contralateral side (data not
shown). Administration of hMSCs into the tail vein of SNI mice
signiﬁcantly reduced mechanical allodynia and thermal hyperal-
gesia on the ipsilateral side (Figures 1A,B) without any change
in the contralateral side (data not show) compared to SNI mice
treated with vehicle.
Stem cell administration did not affect the neurological
functions of the neuropathic mice, once systematically injected
(Figure 1C). Neither the administration procedure nor stem cells
modiﬁed motor coordination. The pain model we used involves
a lesion of two of the three terminal branches of the sciatic nerve
(tibial and common peroneal nerves, leaving the remaining sural
nerve intact), in which neuropathic mice proved to be less able
to walk respect to naïve mice. In order to exclude any further
motor impairment that could possibly be generated by hMSCs,we
applied the Rotarod test to compare SNI/hMSC with SNI/vehicle
treated mice. As shown in Figure 1C, there is no difference in the
motor coordination outcome for these two groups of animals.
HUMAN MSCS HOME NEIGHBORING TO THE NP CONTROLLING AND
PROCESSING SITES AFTER ADMINISTRATION
In order to verify in which tissue the intravenously injected hMSCs
were able to home,we performed speciﬁcRT-PCRampliﬁcation of
human GAPDH gene. The sciatic nerve, lung, dorsal, and ventral
L4–L5 lumbar spinal cord and pre-frontal cortex were harvested
from hMSC-injected neuropathic mice 30 days after SNI injury
(26 days after stem cell injection) to verify the homing of hMSCs
at these sites. Biomolecular analysis conducted on RNA extracted
from these sites revealed a preferential accumulation of hMSCs
in the L4–L5 spinal cord and pre-frontal cortex (Figure 2A). A
very weak band was found in the lung. No GAPDH band was
detectable in the sciatic nerve, thus revealing the speciﬁcity of
hMSC engraftment in the NP controlling and processing areas
(Figure 2A). The primers we used to perform RT-PCR analy-
sis were designed to be speciﬁcally direct to the human GAPDH
gene. However, in order to conﬁrm hMSC homing in the dorsal
and ventral L4–L5 spinal cord of neuropathic mice, we success-
fully veriﬁed that injected hMSCs expressed the surface antigens
CD73 (NT5E, ecto-5′-nucleotidase, E5NT, NTE) using immuno-
cytochemistry (Figures 2B–D). The expression of these antigens is
a validmarker recognized as one of the criteria in the identiﬁcation
of MSCs (Siniscalco et al., 2010). The mouse anti-human CD73
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FIGURE 1 | (A) Effects of human mesenchymal stem cells on reﬂex
withdrawal responses (g, mean±SEM) to mechanical noxious stimuli in
SNI mice. The onset of SNI-induced mechanical allodynia was evaluated in
ipsilateral sides every 10 days starting from day 11 until 90 days after
surgery. Mice showed a signiﬁcant reduction in the threshold to mechanical
stimulation in the ipsilateral paw (*p<0.05 vs. sham-operated mice) after
SNI surgery. Human MSC treatment (on day 4 after SNI surgery, as
indicated by the arrow) prevented the appearance of mechanical allodynia at
11, 20, 30, 40, 50, 60, 70, 80, and 90 days post-SNI (˚p<0.05 vs. SNI mice).
(B) Effects of human mesenchymal stem cells on reﬂex withdrawal
responses (s, mean±SEM) to thermal noxious stimuli in SNI mice. The
onset of SNI-induced thermal hyperalgesia was evaluated in ipsilateral sides
every 10 days starting from day 11 until 90 days after surgery. SNI mice
showed a signiﬁcant reduction in withdrawal latency to radiant heat in the
ipsilateral paw (*p<0.05 vs. sham-operated mice). Human MSC treatment
(on day 4 after SNI surgery, as indicated by the arrow) prevented the
appearance of thermal hyperalgesia 11, 20, 30, 40, 50, 60, 70, 80, and
90 days post-SNI (˚p<0.05 vs. SNI mice). (C) Rotarod motor testing results.
The effects of human mesenchymal stem cell injection on motor
performance in the Rotarod test is shown. Systemic administration of
hMSCs in tail vein of SNI mice had no effect on motor function compared
with vehicle treated SNI mice. Human MSCs were injected on day 4 after
the SNI surgery. Results are expressed as the mean±SEM of the latency
(s; n =5 mice/group). *p<0.05 vs. sham/vehicle.
antibody detects glycosyl phosphatidylinositol (GPI)-anchored
purine salvage enzyme expressed on the surface of hMSCs. The
antibody does not cross-react with other human antigens or with
FIGURE 2 | (A) Representative agarose gel blot analysis for human GAPDH
gene of 30 days-SNI/hMSCs mice following RT-PCR is shown. Lane (1) lung;
lane (2) sciatic nerve; lane (3) ventral L4–L5 spinal cord and (4) dorsal L4–L5
spinal cord; lane (5) pre-frontal cortex; lane (6) DNA ladder marker. The
analysis of mRNA levels was carried out by the “Gel Doc 2000 UV System”
(Bio-Rad, Hercules, CA, USA). RT-PCR analysis revealed a preferential
accumulation of hMSCs to the L4–L5 spinal cord (both ventral and dorsal
areas) and pre-frontal cortex. Very weak band was found from lung. No
GAPDH band was detectable in sciatic nerve, thus revealing the speciﬁcity
of hMSC engraftment at the NP controlling and processing areas. (B)
Representative cross-section of mouse whole L4–L5 spinal cord area from
hMSC-treated 30 days-neuropathic mice (26 days post-hMSC injection). (B’)
Representative cross-section of mouse whole L4–L5 spinal cord area from
vehicle treated 30 days-neuropathic mice showing no staining for human
speciﬁc CD73. (C,D) Human MSCs expressed lineage-speciﬁc antigens at
26 days post-injection in vivo. Representative ﬂuorescent photomicrograph
of hMSCs showing immunocytochemistry for CD73. Area in white
rectangle insets is shown: (C) ventral spinal cord; (D) dorsal spinal cord;
left: cell nuclei were counterstained with DAPI (blue ﬂuorescence); middle:
CD73-positive hMSCs emitted red ﬂuorescence; right: pictures with both
red and blue ﬂuorescence were merged. Scale bars: 100μm.
other mouse (host) antigens. Injected hMSCs were positive for
these lineage-speciﬁc antigens 26 days after the administration
procedure.
HUMAN MESENCHYMAL STEM CELLS REDUCE IL-1β AND IL-17
PRO-INFLAMMATORY PROTEIN LEVELS AND INCREASE IL-10
ANTI-INFLAMMATORY PROTEIN LEVELS IN NEUROPATHIC MICE
To verify an anti-inﬂammatory or immunomodulatory action for
stem cell-mediated anti-allodynic/anti-hyperalgesic mechanisms
we checked inﬂammatory interleukin levels by western blot analy-
sis 30 days after sciatic nerve surgery. We chose this time point
on the basis of behavioral results, indicating a slight maximum
anti-nociceptive action taken by hMSCs at this time.
Human MSCs were able to reduce the pro-inﬂammatory
interleukin IL-1β and IL-17 protein levels in the lumbar
L4–L5 spinal cord of SNI/hMSC-treated mice compared to
SNI/vehicle mice (Figure 3). Conversely, hMSCs did trigger anti-
inﬂammatory interleukin IL-10 over-production in the spinal
cord of SNI/hMSCs-treated mice compared to SNI/vehicle mice
(Figure 3).
For all proteins examined, naïve and sham animals showed no
differences in the expression levels (data not shown).
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FIGURE 3 | Representative western blot analysis for IL-1β, IL-17, IL-10,
CD206, and housekeeping β-tubulin mouse proteins are shown.The
semi-quantitative analysis of protein levels was carried out by the “Gel Doc
2000 UV System” (Bio-Rad, Hercules, CA, USA). Human MSC treatment (on
day 4 after SNI surgery) reduced the protein levels of pro-inﬂammatory
interleukins IL-1β and IL-17 in hMSC-treated 30 days-neuropathic mice
(SNI+hMSCs) respect to vehicle treated 30 days-neuropathic mice
(SNI+ vehicle). Human MSC treatment (on day 4 after SNI surgery) increased
the protein levels of anti-inﬂammatory interleukin IL-10 and activated
anti-inﬂammatory macrophage marker CD206 in hMSC-treated
30 days-neuropathic mice (SNI+hMSCs) respect to vehicle treated
30 days-neuropathic mice (SNI+ vehicle). Upper graph shows IL-1β/β-tubulin
normalized values as obtained by immunoblot analysis. Human MSC
treatment (on day 4 after SNI surgery) reduced the protein levels of IL-1β
interleukin in hMSC-treated 30 days-neuropathic mice (SNI+hMSCs) respect
to vehicle treated 30 days-neuropathic mice (SNI+ vehicle). ANOVA, followed
by Student–Neuman–Keuls post hoc test, was used to determine the
statistical signiﬁcance among groups. *p<0.01 was considered statistically
signiﬁcant. Lower graph shows CD206/β-tubulin normalized values as
obtained by immunoblot analysis. Human MSC treatment (on day 4 after SNI
surgery) increased the protein levels of activated anti-inﬂammatory
macrophage marker CD206 in hMSC-treated 30 days-neuropathic mice
(SNI+hMSCs) respect to vehicle treated 30 days-neuropathic mice
(SNI+ vehicle). ANOVA, followed by Student–Neuman–Keuls post hoc test,
was used to determine the statistical signiﬁcance among groups. *p<0.01
was considered statistically signiﬁcant.
HUMAN MESENCHYMAL STEM CELLS INCREASE CD206 MACROPHAGE
MARKER IN THE SPINAL CORD OF SNI MICE
To test the hypothesis that hMSCs may induce an anti-
inﬂammatory phenotype in macrophages, we examined levels
of CD206 protein, a well-known marker for anti-inﬂammatory
macrophages (Porcheray et al., 2005), by western blot analysis
30 days after sciatic nerve surgery.
Indeed, hMSCs were able to increase the CD206 levels in
the L4–L5 spinal cord of SNI/hMSC-treated mice compared to
SNI/vehicle mice (Figure 3).
T LYMPHOCYTES AND ASTROCYTES ARE RESPONSIBLE RESPECTIVELY
FOR PRO-INFLAMMATORY IL-17 AND IL-1β PRODUCTION IN THE
SPINAL CORD OF SNI MICE
As described above, hMSCs were able to decrease the levels of
pro-inﬂammatory interleukin IL-17 protein in the lumbar L4–L5
spinal cord of SNI/hMSC-treated mice compared to SNI/vehicle
mice. To verify immunomodulatory action mediated by hMSCs
further, we double stained for IL-17 and for the T lymphocyte
marker CD4. IL-17 positive proﬁles were found co-localized with
CD4 T lymphocyte marker positive proﬁles in the L4–L5 spinal
cord of 30 days NP mice (Figure 4).
Human MSCs were able to reduce the levels of pro-
inﬂammatory interleukin IL-1β in the L4–L5 spinal cord of
SNI/hMSC-treated mice compared to SNI/vehicle mice. In order
to verify which cells were responsible for the pro-inﬂammatory
production of IL-1β, we double stained for IL-1β and GFAP and
Iba-1 cyto-speciﬁc markers, respectively. IL-1β positive proﬁles
were found co-localizedwithGFAPastrocyticmarker positive pro-
ﬁles (Figure 4), but not with speciﬁc Iba-1 microglial marker (data
not shown) in the L4–L5 spinal cord of 30 days NP mice.
DISCUSSION
In this study we demonstrated for the ﬁrst time that a sin-
gle systemic injection of hMSCs into the tail vein was able to
reduce NP-like behaviors and to modify molecular and cellular
pain-associated pathways.
We chose the tail vein as the injection site for systemic delivery
of hMSCs since the present study focused on (i) further clariﬁ-
cation of the beneﬁcial effects of stem cells in NP, without any
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FIGURE 4 | Representative cross-section of mouse L4–L5 spinal cord
from 30days-neuropathic mice. (A) First: IL-17 positive proﬁles (green
ﬂuorescent) in vehicle treated 30 days-neuropathic mice (SNI+ vehicle).
Second: CD4 positive proﬁles (red ﬂuorescent) in vehicle treated
30 days-neuropathic mice. Third: double labeling of IL-17 and CD4 positive
proﬁles. Fourth: higher magniﬁcation showing that the cells expressing
IL-17 wereT lymphocytes. Cell nuclei were counterstained with DAPI (blue
ﬂuorescence). Scale bars: 100μm. (B) First: IL-1β positive proﬁles (green
ﬂuorescent) in vehicle treated 30 days-neuropathic mice. Second: GFAP
positive proﬁles (red ﬂuorescent) in vehicle treated 30 days-neuropathic
mice. Third: double labeling of GFAP and IL-1β positive proﬁles. Fourth:
higher magniﬁcation indicating that the cells expressing IL-1β were
astrocytes. Cell nuclei were counterstained with DAPI (blue ﬂuorescence).
Scale bars: 100μm. (C) First: IL-1β proﬁles (green ﬂuorescent) in
hMSC-treated 30 days-neuropathic mice (SNI+hMSCs). Second: IL-17
proﬁles (green ﬂuorescent) in hMSC-treated 30 days-neuropathic mice
(SNI+hMSCs). The absence of positive staining indicates that injected
hMSCs were able to reduced the protein levels of pro-inﬂammatory
interleukins IL-1β and IL-17, conﬁrming western blot analysis results.
invasive surgical procedure, as performed in our previous work
(Siniscalco et al., 2010), and (ii) following the clinical trial pro-
tocols currently used more effectively (see www.clinicaltrials.gov).
Indeed, in all clinical use of human adult bone marrow derived,
culture-expanded MSCs, whether autologous or allogeneic, no
adverse events were recorded. This means that cell isolation and
culture expansion is safe and clinical beneﬁts from the intravenous
delivery of hMSCs could be observed (Caplan, 2009).
Once hMSCs had been injected into neuropathic mice, we
focused our biomolecular and morphological experiments on the
L4–L5 spinal cord, since there is evidence that this may be the pri-
mary site directly involved inNP-associated cellular andmolecular
changes (Maione et al., 2002; de Novellis et al., 2004).
HUMAN MESENCHYMAL STEM CELL MECHANISM OF ACTION
Despite hMSCs having been employed in several clinical trials,
their mechanism of action is still unknown. Their main advan-
tage is that they are probably immunomodulatory and versatile
in their action due to their secreted bioactive anti-inﬂammatory
and regenerative molecules (Bonﬁeld and Caplan, 2010). Indeed,
hMSC-mediated secretion of a broad range of bioactivemolecules,
such as growth factors, cytokines, and chemokines, is their most
biologically signiﬁcant role under injury conditions rather than
their ability to differentiate (Pan et al., 2007; Pisati et al., 2007;
Siniscalco et al., 2008, 2010; Meirelles Lda et al., 2009). This fact
exceeds the thesis based on differentiation, engraftment, or de novo
regeneration from transplanted stem cells to a point of view in
which the functional beneﬁt derived from hMSC transplantation
may be due to their ability to produce factors that activate endoge-
nous restorative mechanisms. A combination of neurotrophic
and anti-inﬂammatory factors produced by transplanted hMSCs
could be the mechanism underlying the functional improvement
in NP seen after hMSC injection shown in the present study.
Indeed, MSC paracrine effects can be divided into several types:
trophic, immunomodulatory, anti-scarring, and chemoattractant.
Themost surprising feature of MSCs is their extraordinary and still
partially unexplained immunomodulatory property (Nauta and
Fibbe, 2007; Schipani and Kronenberg, 2009). Mesenchymal SCs
have a potent immunosuppressive capacity mediated via soluble
factors. These immunomodulatory effects of MSCs consist of the
inhibition of the proliferation of CD8+ and CD4+ T lymphocytes
and natural killer (NK) cells, suppression of immunoglobulin pro-
duction by plasma cells, inhibition of maturation of dendritic cells
(DCs) and stimulation of the proliferation of regulatory T cells
(Hoogduijn et al., 2010). It has been demonstrated that MSCs are
able to inhibit T lymphocyte proliferation and pro-inﬂammatory
cytokine production after mitogen or cellular stimulation in vitro
(Di Nicola et al., 2002; Beyth et al., 2005), as well as in vivo (Dazzi
and Marelli-Berg, 2008).
INVOLVEMENT OF THE IMMUNE SYSTEM IN THE NEUROPATHIC PAIN
SYNDROME
The development of NP involves not only neuronal pathways, but
also components of the peripheral immune system (Scholz and
Woolf, 2007). NP shows a presence of inﬂammation at the site
of the injured nerves. This inﬂammatory response results in the
concentration and activation of innate immune cells at the site of
tissue injury. These cells release immunoactive substances, such
as cytokines, neurotrophic factors, and chemokines, which initi-
ate local actions and can result in a more generalized immune
response (Vallejo et al., 2010). Spinal cord T lymphocytes are
responsible for mediating adaptive immune responses and are
involved in NP (Zenonos and Kim, 2010). Indeed, NP-activated
CD4+ cells are able to produce IL-17, the interleukin responsible
for modulating immune response during inﬂammation. Inter-
estingly, it has been demonstrated that IL-17 could attract and
activate macrophages in a NP condition (Kleinschnitz et al., 2006).
Moreover, emerging studies highlight a key role played by
macrophages in the pathogenesis of NP (Vega-Avelaira et al., 2009;
Mika et al., 2010;Otoshi et al., 2010). In theNPcondition,activated
macrophages are able to over-express pro-nociceptive mediators,
among which the inﬂammatory protein-1α (MIP-1α), which is
in turn capable to up-regulate the potent pro-inﬂammatory/pro-
nociceptive interleukin IL-1β (Wang et al., 2008;Maeda et al., 2009;
Kiguchi et al., 2010; Siniscalco et al., 2010).
EVIDENCE OF HUMAN MESENCHYMAL STEM CELL MECHANISM OF
ACTION IN NEUROPATHIC PAIN
It is worth noting that injected hMSCs were able to down-regulate
the NP-increased IL-1β protein level in the spinal cord of NP
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mice, together with a reduced protein level of pro-inﬂammatory
interleukin IL-17. This hMSC anti-inﬂammatory action could be
mediated by switched macrophage phenotypes, as conﬁrmed by
the up-regulation of CD206 protein level in the spinal cord of NP
mice that we found after hMSC administration. Indeed, hMSCs
couldmediate switching fromM1pro-inﬂammatorymacrophages
to M2 anti-inﬂammatory macrophages (Kim and Hematti, 2009).
These M2 cells highly express the cell surface marker CD206
(Porcheray et al., 2005) and are strongly involved in the resolu-
tion of inﬂammation through trophic factor synthesis and intense
phagocytic activities. In addition,MSC-educated macrophages are
able to over-express anti-inﬂammatory cytokines, above all IL-10
(KimandHematti, 2009).Our results suggest that hMSC-educated
macrophages could be the major type of effector cell through
which hMSCs might exert their therapeutic effects.
How hMSCs work to switch macrophages is still under investi-
gation. Emerging studies suggest that hMSC immune-modulating
properties are mediated by a novel contact-dependent mechanism
involving cell–cell interaction (Gur-Wahnon et al., 2009). It has in
fact been demonstrated that hMSCs block antigen-presenting cell
(APC) maturation in a contact-dependent manner (Gur-Wahnon
et al., 2007). The novel contact-dependent mechanism is different
from that mediated by the release of soluble factors and cytokines.
The beneﬁcial effects mediated by hMSCs shown here may be the
result of both mechanisms, suggesting that they have different yet
complementary biological functions. In our study, in spinal cord
and cortex niches, hMSCs could secrete molecules to commu-
nicate with and respond to other cell types, as well as inducing
phenotypic macrophage switching through a contact-dependent
mechanism. NP progression may be mediated by modiﬁcations
in glial responses to nociception (de Novellis et al., 2004). It is
noteworthy that also NP-activated astrocytes are able to produce
IL-1β (Siniscalco et al., 2010). Our results indicate that astrocytes,
rather than microglial cells, may contribute to long-lasting NP
maintenance. hMSC-mediated reduction in IL-1β levels, consis-
tently with our earlier results (Siniscalco et al., 2010), suggests that
hMSCs were also able to affect the functionality of these cell types,
probably by inﬂuencing the glial–cytokine–neuronal interactions.
HOMING OF HUMAN MESENCHYMAL STEM CELL IN NEUROPATHIC
PAIN CONTROLLING AREAS
Our data indicate that 26 days after injection, injected hMSCs were
able to home to CNS areas critically involved in NP signaling: the
dorsal and ventral L4–L5 spinal cord and pre-frontal cortex. Dri-
ven by chemokine signals, stem cells are highly capable of homing
to sites of injury (Corcione et al., 2006; Sze et al., 2007), where they
exert a local and/or systemic immunosuppressive action, thus lim-
iting the inﬂammatory or immune reactions (Ceradini et al., 2004;
Forte et al., 2008; Mattsson, 2008; Siniscalco et al., 2010). In light
of our results demonstrating a signiﬁcant reduction in NP after
hMSC treatment, the spinal cord and the cortical brain areas may
represent critical substrates inwhich to analyze speciﬁc biomarkers
involved in NP processing (Jasmin et al., 2003; Zhuo, 2007; Fuccio
et al., 2009; Neugebauer et al., 2009; Siniscalco et al., 2010). In
order to perform RT-PCR analysis, we used primer pairs designed
to be speciﬁcally direct to GAPDH human gene. Thus, the human
speciﬁcity of these PCR primers that we used to track hMSCs
allowed us to ensure that stem cells located in these areas involved
in NP modulation were heterologous injected stem cells. In addi-
tion, and as further conﬁrmation, we successfully stained injected
hMSCs with the cyto-speciﬁc marker CD73 in both the dorsal
and ventral L4–L5 spinal cord. We did not perform a time-course
tracking of injected hMSCs during the progression of NP. How-
ever, it has already been demonstrated that hMSCs transplanted
into the mouse tail vein were mainly found trapped in the lung ini-
tially (Gao et al., 2001; Ankrum and Karp, 2010). It is interesting
to note that these lung trapped hMSCs are able to secrete anti-
inﬂammatory factors (Lee et al., 2009). Such a possibility could
also be the case in our study, where a percentage of hMSCs could
have been ﬁrst trapped in the lung, as demonstrated by GAPDH
weak band detected by RT-PCR, where they still secreted anti-
inﬂammatory factors, after which they were probably removed.
Another percentage of injected hMSCs could have been trapped
in the spinal cord and cortex areas, where they homed until up
to 26 days post-injection, recruited by NP-associated molecular
and cellular changes. Indeed, hMSCs are sensitive to site-speciﬁc
microenvironments. Due to this fact, pro-nociceptive molecules
released in these areas following injury-induced changes in their
expressionwere able to recruit hMSCs. Recruited hMSCswere able
to integrate into the tissue, survive, and drive functional improve-
ment. In addition, we did not rule out the possibility that hMSCs
could increase the expression of several growth factors, such as
nerve growth factor (NGF) and brain-derived neurotrophic factor
(BDNF; Mahmood et al., 2004). However, further biomolecular
experiments on cortex area will be needed.
We cannot exclude the possibility that injected hMSCs survived
more than 3 months post-injection. Nevertheless, whether hMSCs
are still present or not, what is fundamental is that they determine
long-lasting recovery from NP symptoms.
In conclusion, we show here that hMSCs are able to reduce
mechanical allodynia, thermal hyperalgesia and modify cellular
and molecular NP mechanisms, once systemically administered
into the mouse tail vein. We demonstrated that hMSC treatment
reduced theprotein levels of thepro-inﬂammatory interleukins IL-
1β and IL-17 and increased those of anti-inﬂammatory interleukin
IL-10, as well as the macrophage marker CD206. As a possible
mechanism of action of hMSCs in reducing NP, we suggest that
hMSCs could exert their beneﬁcial action through a restorative
mechanism involving: (i) a cell-to-cell contact activation mecha-
nism, throughwhich spinal cordhomedhMSCs are responsible for
switching pro-inﬂammatory macrophages to anti-inﬂammatory
macrophages; (ii) the secretion of a broad spectrum of molecules
to communicate with other cell types. Our ﬁndings on injected
hMSC homing to the site of NP processing provide evidence that
the administration of hMSC may be a more suitable long-lasting
therapy than currently available anti-neuropathic drugs, support-
ing the hypothesis that hMSCs may deliver bioactive agents in a
site-speciﬁc manner, with enduring modulation on the immune–
neural cell cross-talk in a rather differentway fromhow the current
classical drugs work (Bonﬁeld and Caplan, 2010).
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